Business
/C O R R E C T I O N -- MyOme, Inc/
Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance MyOme's strategic roadmap including MyOme's Proactive Health (MPH) Trial — a large-scale prospective trial that aims to prove enhanced patient outcomes and substantial cost savings resulting from use of whole-genome sequencing (WGS) combined with MyOme's AI-integrated risk models
About this update from Illumina, Inc.
[{"type":"text","content":"In the news release, Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually, issued Dec. 11 by MyOme, Inc over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:","length":372,"tagName":"p"},{"type":"heading","content":"Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually","length":167,"tagName":"h3","attribs":{}},{"type":"text","content":"Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. ","length":181,"tagName":"p"},{"type":"text","content":"SAN DIEGO and MENLO PARK, Calif., Dec. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance MyOme's strategic roadmap including MyOme's Proactive Health (MPH) Trial — a large-scale prospective trial that aims to prove enhanced patient outcomes and substantial cost savings resulting from use of whole-genome sequencing (WGS) combined with MyOme's AI-integrated risk models (IRMs) for common, chronic conditions, cancers, and rare disease.","length":647,"tagName":"p"},{"type":"image","alt":"Illumina (PRNewsfoto/MyOme, Inc)","displaySize":"","headline":null,"caption":"Illumina (PRNewsfoto/MyOme, Inc)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/2e3f480dadb4ec0ef2bf3b44b53e3dd4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3EGxxcK6viafb8p093Ekbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/2e3f480dadb4ec0ef2bf3b44b53e3dd4","width":400,"height":97}},"href":"https://mma.prnewswire.com/media/2843192/illumina_full_logo_CMYK_pumpkin.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The U.S. spends approximately $5 trillion annually on healthcare. Health economic and outcomes modelin...